| abstract |
The present invention relates to the use of a pharmaceutical composition of remoglyflozin etabonate, an SGLT2 inhibitor for treating primary sclerosing cholangitis (PSC). Methods and compositions related to the present invention describe PSC symptoms such as ascites accumulation, hepatic encephalopathy, varicose vein development, jaundice, varicose vein bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer. Can improve or maintain clinical outcome. [Selection diagram] Fig. 3 |